Soleno Therapeutics Is Maintained at Outperform by Oppenheimer
Soleno Therapeutics Analyst Ratings
Oppenheimer Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Raises Target Price to $73
Piper Sandler Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $93
Stifel Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $74
A Quick Look at Today's Ratings for Soleno Therapeutics(SLNO.US), With a Forecast Between $65 to $75
Stifel Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $74
Soleno Therapeutics Is Maintained at Buy by Stifel
Stifel Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Raises Target Price to $74
Piper Sandler Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $93
Piper Sandler Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)
Soleno Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Soleno Therapeutics, Maintains $67 Price Target
Piper Sandler Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $93
H.C. Wainwright Initiates Soleno Therapeutics(SLNO.US) With Buy Rating, Announces Target Price $70
Buy Rating for Soleno Therapeutics Amidst Favorable Regulatory Developments for DCCR
Piper Sandler Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $93
Soleno Therapeutics Price Target Raised to $65.00/Share From $59.00 by Oppenheimer
Soleno Therapeutics Analyst Ratings
Oppenheimer Sticks to Its Buy Rating for Soleno Therapeutics (SLNO)
No Data
No Data